Nuance Investments LLC Sells 1,017,410 Shares of Hologic, Inc. $HOLX

Nuance Investments LLC reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 73.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 361,449 shares of the medical equipment provider’s stock after selling 1,017,410 shares during the period. Hologic accounts for about 2.5% of Nuance Investments LLC’s investment portfolio, making the stock its 15th largest holding. Nuance Investments LLC owned about 0.16% of Hologic worth $24,394,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Hologic by 10.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares during the last quarter. Empowered Funds LLC increased its position in Hologic by 27.7% during the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after buying an additional 3,790 shares in the last quarter. Vontobel Holding Ltd. increased its position in Hologic by 0.8% during the 2nd quarter. Vontobel Holding Ltd. now owns 39,793 shares of the medical equipment provider’s stock valued at $2,593,000 after buying an additional 318 shares in the last quarter. Blue Trust Inc. boosted its holdings in Hologic by 9.0% in the second quarter. Blue Trust Inc. now owns 8,322 shares of the medical equipment provider’s stock worth $542,000 after acquiring an additional 685 shares in the last quarter. Finally, Aberdeen Group plc boosted its holdings in Hologic by 2.8% in the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock worth $15,964,000 after acquiring an additional 6,589 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HOLX. BTIG Research restated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Morgan Stanley upped their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Stock Performance

Shares of HOLX stock opened at $74.81 on Monday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The company has a 50 day moving average price of $74.87 and a 200-day moving average price of $71.31. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.36. The firm has a market capitalization of $16.70 billion, a PE ratio of 31.17, a P/E/G ratio of 2.23 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company earned $0.87 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.